Vemurafenib (PLX4032, Plexxikon or RG7204, Roche Pharmaceuticals), a potent inhibitor of BRAF (BRAFi) with high selectivity for BRAF V600E, was the first molecularly targeted therapy licensed for the treatment of advanced melanoma [6]. This evidence concerns the gene BRAF and melanoma.